Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies
Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies
The phosphoinositide 3-kinase/mammalian target of rapamycin/protein kinase B (PI3K/mTOR/Akt) signaling pathway is central to a plethora of cellular mechanisms in a wide variety of cells including leukocytes. Perturbation of this signaling cascade is implicated in inflammatory and autoimmune disorders as well as hematological malignancies. Proteins within the PI3K/mTOR/Akt pathway therefore represent attractive targets for therapeutic intervention. There has been a remarkable evolution of PI3K inhibitors in the past 20 years from the early chemical tool compounds to drugs that are showing promise as anticancer agents in clinical trials. The use of animal models and pharmacological tools has expanded our knowledge about the contribution of individual class I PI3K isoforms to immune cell function. In addition, class II and III PI3K isoforms are emerging as nonredundant regulators of immune cell signaling revealing potentially novel targets for disease treatment. Further complexity is added to the PI3K/mTOR/Akt pathway by a number of novel signaling inputs and feedback mechanisms. These can present either caveats or opportunities for novel drug targets. Here, we consider recent advances in 1) our understanding of the contribution of individual PI3K isoforms to immune cell function and their relevance to inflammatory/autoimmune diseases as well as lymphoma and 2) development of small molecules with which to inhibit the PI3K pathway. We also consider whether manipulating other proximal elements of the PI3K signaling cascade (such as class II and III PI3Ks or lipid phosphatases) are likely to be successful in fighting off different immune diseases.
1027-1054
Foster, J.G.
81b94bce-d994-496c-b069-4f652b4a56fc
Blunt, M.D.
b1109de3-6045-4bc3-bd77-6cf26504697d
Carter, E.
3289adb3-c959-4303-a515-e17bf19bfa24
Ward, S.G.
19512430-2b0a-409f-a3df-cd2896e04bbf
October 2012
Foster, J.G.
81b94bce-d994-496c-b069-4f652b4a56fc
Blunt, M.D.
b1109de3-6045-4bc3-bd77-6cf26504697d
Carter, E.
3289adb3-c959-4303-a515-e17bf19bfa24
Ward, S.G.
19512430-2b0a-409f-a3df-cd2896e04bbf
Foster, J.G., Blunt, M.D., Carter, E. and Ward, S.G.
(2012)
Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.
Pharmacological Reviews, 64 (4), .
(doi:10.1124/pr.110.004051).
(PMID:23023033)
Abstract
The phosphoinositide 3-kinase/mammalian target of rapamycin/protein kinase B (PI3K/mTOR/Akt) signaling pathway is central to a plethora of cellular mechanisms in a wide variety of cells including leukocytes. Perturbation of this signaling cascade is implicated in inflammatory and autoimmune disorders as well as hematological malignancies. Proteins within the PI3K/mTOR/Akt pathway therefore represent attractive targets for therapeutic intervention. There has been a remarkable evolution of PI3K inhibitors in the past 20 years from the early chemical tool compounds to drugs that are showing promise as anticancer agents in clinical trials. The use of animal models and pharmacological tools has expanded our knowledge about the contribution of individual class I PI3K isoforms to immune cell function. In addition, class II and III PI3K isoforms are emerging as nonredundant regulators of immune cell signaling revealing potentially novel targets for disease treatment. Further complexity is added to the PI3K/mTOR/Akt pathway by a number of novel signaling inputs and feedback mechanisms. These can present either caveats or opportunities for novel drug targets. Here, we consider recent advances in 1) our understanding of the contribution of individual PI3K isoforms to immune cell function and their relevance to inflammatory/autoimmune diseases as well as lymphoma and 2) development of small molecules with which to inhibit the PI3K pathway. We also consider whether manipulating other proximal elements of the PI3K signaling cascade (such as class II and III PI3Ks or lipid phosphatases) are likely to be successful in fighting off different immune diseases.
This record has no associated files available for download.
More information
Published date: October 2012
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 392717
URI: http://eprints.soton.ac.uk/id/eprint/392717
ISSN: 0031-6997
PURE UUID: edb30ed7-0a3d-4746-a1da-f610030c170b
Catalogue record
Date deposited: 14 Apr 2016 14:10
Last modified: 15 Mar 2024 03:46
Export record
Altmetrics
Contributors
Author:
J.G. Foster
Author:
E. Carter
Author:
S.G. Ward
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
